FibroBiologics (NASDAQ:FBLG) Receives Buy Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $16.00 target price on the stock.

FBLG has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a research report on Thursday. Rodman & Renshaw assumed coverage on shares of FibroBiologics in a report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Price Performance

FBLG stock traded down $0.41 during trading hours on Thursday, reaching $1.32. 862,288 shares of the stock were exchanged, compared to its average volume of 365,524. The firm’s 50-day moving average is $1.98 and its 200-day moving average is $2.49. FibroBiologics has a 12 month low of $1.08 and a 12 month high of $17.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company acquired a new position in shares of FibroBiologics during the 3rd quarter worth about $32,000. Jane Street Group LLC acquired a new position in FibroBiologics during the third quarter worth approximately $37,000. Intech Investment Management LLC acquired a new position in FibroBiologics during the fourth quarter worth approximately $25,000. Virtu Financial LLC bought a new stake in FibroBiologics in the fourth quarter valued at approximately $30,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of FibroBiologics in the fourth quarter valued at approximately $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.